Overview

Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naïve Patients Starting Raltegravir Plus Tenofovir/Emtricitabine

Status:
Completed

Trial end date:
2011-11-01

Target enrollment:

Participant gender:

Summary

The intensification with maraviroc in recently HIV-1-infected patients of a preferred gold-standard triple therapy composed of raltegravir plus tenofovir/emtricitabine could accelerate the decay of the HIV-1 reservoir in latently infected cells established early in HIV-1 infection. This could provide further insight into this area, decrease the size of latent reservoir, and translate into clinical benefits for patients.

Phase:

Phase 3

Details

Lead Sponsor:

Germans Trias i Pujol Hospital

Treatments:

Emtricitabine
Maraviroc
Raltegravir Potassium
Tenofovir